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Stefin A, a cysteine proteinase inhibitor of the cyst&in superfamily, has been found to be most abundant in epidermal cells. In order to determine 
its ~llular function, we have expressed human stefln A in ~cherich~ coli using plasmid expression vectors under the control of bacteriophage 
T7 RNA polymerase. The heat-stable, antibody-~sitive bacterial product was isolated using a papain-Sharon affinity column and was shown 
to inhibit two cysteine proteinases, papain and human cathepsin B. Recombinant stefin A may have commercial and therapeutic potential in situa- 
tions requiring inhibition of cysteine proteinase activities, and in cosmetics, as an ingredient in skin creams. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Proteinases are implicated in a variety of cellular 
functions, and their occurrence emphasizes the impor- 
tance of proteolysis in the control of cellular processes 
[l]. We have been interested in cysteine proteinases 
such as cathepsin B because of their potential role in 
diseases including tumor metastasis [2]. For the four 
groups of proteinases, the serine, cysteine, aspartic and 
metallo-types, many proteinase inhibitors are known 
[3]. The protein proteinase inhibitors for cysteine pro- 
teinases are members of the cystatin superfamily. With 
a wide phylogenetic distribution, the members are 
divided into three families: stefins, cystatins and 
kininogens; at least one human hereditary disease is 
caused by a cystatin mutation [4]. The stefins are low- 
mol~ul~-Wright, carbohydrate-free, the~ostable 
protein molecules. Human and rat stefins have been 
characterized, with stefin B demonstrating a general 
tissue distribution and stefin A found predominantly in 
epidermal keratinocytes and polymorphonuclear 
leucocytes [5,6]. Our study on keratinocyte gene ex- 
pression led us to human stefin A (also known as 
cystatin A) complementary DNA clones [7]. Although 
a mouse stefin A cDNA clone has been independently 
reported [8], to our knowledge, ours are the only 
human clones. Since it took 80 1 of fresh human blood 
for the first characterization of stefin A [9], we decided 
to make the recombin~t protein for functional studies. 
2. I. Construction of expression vectors 
Previously, we used the PET series of expression vectors for human 
cathepsin B [lo], and we did the same for stefin A. The &oRI- 
BarnHI 1.5 kb fragment from stefin A cDNA clone 242 171, first 
subcloned in pUC9, was isolated and cut with restriction enzymes 
NluIV and SauJAI. This generated a 384 bp fragment containing the 
complete stefin A coding region. After Klenow fill-in and BumHI 
linker addition, the insert was cloned into pBR322 and transferred to 
pET3a, pET3b and pET3c expression vectors (in E. coli host 
HMS174). Orientation of cDNA insertion was determined based on 
HincII restriction pattern. Six clones, designated pMC31 through 
pMC36, were selected to correspond to stefin A cDNA insert in the 
correct and opposite direction for the three vectors (see fig. 1). These 
were used to transform the expression host BLZl(DE3)pLysS and 
tested for stefin A production. Bacteria were grown in nutrient broth 
containing ampicillin and c~or~phenico~ fusion protein produc- 
tion was induced by 1 mM IPTG (isopropyl-~-D-thiog~actoside), 
and cefls were pelleted and frozen at -70°C. 
2.2. Isolation of recombinant protein 
For affinity chromatography, the bacterial Iysate (pMC33) was 
sonicated in buffer (10 mM Tris-HCl, pH 7.6) containing 2 mM 
EDTA, the debris was removed by centrifugation, and the sample 
heat-treated (lOO°C for 15 min). After centrifugation, the heat- 
soluble fraction was loaded onto a papain-Sepharose column (from 
Pierce, pretreated with buffer containing 0.5 M NaCI) [ll]. After 
flow-through of unbound material, the column was washed with buf- 
fer containing 3 M KCI, and bound material was eluted with JO mM 
NarPOd, pH 11.5, containing 0.5 M NaCl. The collected fraction, 
neutralized with 1 M HCI, was found to be stefin A fusion protein 
by gel analysis. Protein quantitation was done by the BCA (bicin- 
choninic acid) method (from Pierce). 
2.3. Assays o~protein~e inhibiio~ 
Correspondence address: D. Fong, Department of Biological 
Sciences, Rutgers, The State University of New Jersey, Piscataway. 
NJ 088551059, USA 
The peptide Z-Arg-Arg-AFC (7-amino-t~fluorom~hylcouma- 
rin, from Enzyme Systems Products) was used as a substrate for 
cathepsin B 112). Dissolved in dimethyl formamide at 10 mg/ml, it 
was diluted to 25 #M in buffer (0.2 M sodium phosphate, pH 6) con- 
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taining 5 mM dithiothreitol and 1 mM EDTA. For a simple assay in 
microtiter plates, bacterial ysates (typically 30 ~1) or column eluates 
were pretreated with human liver cathepsin B (from Calbiochem, 
diluted to lOag/ml, typically 5 ~1) for 10 min at room temperature, 
and then 50 pi of substrate was added. After incubation for 15 min 
at 37”C, the plate was viewed under a UV transilluminator 
(Fotodyne). The peptide AFC has blue fluorescence, whereas the free 
AFC has green fluorescence. 
For inhibition constants, the activities of papain (Sigma; repurified 
on Sephadex G-50) and cathepsin B (Calbiochem) were determined in 
the presence of appropriately diluted inhibitor and 0.1 M acetate buf- 
fer, pH 5.5, or citrate phosphate buffer, pH 6.2, respectively, follow- 
ing a 10 min activation at 37°C with 5 mM dithiothreitol and 2 mM 
EDTA. The assays were terminated by the addition of 100 mM 
sodium monochloroacetate, containing 30 mM sodium acetate and 
70 mM acetic acid [13]. 
2.4. Western blot analysis 
Protein was transferred from gel to filter (0.2,um nitrocellulose 
from Sartorius) using Western blot technique [lo]. After shaking for 
1 h at room temperature with TTBS (Tris-buffered saline, 20 mM 
Tris-HCl, pH 7.5, 0.5 M NaCl containing 0.05% Tween-2(l), the 
filter was treated with 1:2000 dilution of rabbit antiserum to rat low- 
molecular-weight cysteine proteinase inhibitor [14]. The antiserum 
was precleared with an unrelated bacterial ysate before use (using 
pMC4) [lo]. After overnight incubation, the filter was washed in 
TTBS and treated for 1 h with a secondary antibody (1: 2000 dilution 
of affinity purified goat anti-rabbit antibody conjugated to 
horseradish peroxidase, from Southern Biotechnology). After 
washings in TTBS and TBS, the filter was developed with the 
chromogenic substrate Indophane Red (from Vio-medics). 
3. RESULTS 
The coding segment of stefin A from cDNA clone 
242 [7] was ligated into the expression vector, resulting 
in the plasmid designated as pMC33 (fig.1). A control 
pIasmid, with the stefin DNA segment cloned in the op- 
posite orientation, was named pMC34. In the ap- 
propriate bacterial host, recombinant stefin protein 
was detected. Since it is a fusion protein cont~ning T7 
#lO protein amino-terminal sequence (11 amino acid 
residues), BarnHI linker sequence (3 residues), 5’ se- 
quence of the cDNA (12 residues), and the stefin A 
coding region (98 residues), its apparent molecular 
mass was 16 kDa by SDS-polyacrylamide gel analysis 
(fig.2A). The calculated value was 14 3 13 Da; the larger 
apparent molecular weight may result from a change in 
mobility due to protein configuration change). The 
protein was inducible by IPTG, but there was a basal 
Fig.1. Human stefin A cDNA plasmid pMC33 
A 
12345678 
B 
12345678 
Fig.2. SDS-polyacrylamide gel electrophoresis and Western blot of 
recombinant stefin A. Lanes: 1 and 8, molecular mass standards 
(prestained standards from Bethesda Research Laboratories, the six 
bands are 43, 29, 18, 14, 6 and 3 kDa in size); 2-4, from plasmid 
pMC34; 5-7, from pMC33. The three lanes denote total bacterial 
lysate, heat soluble and insoluble fractions. For 12.5% minigef, 1Ocg 
protein was loaded for lanes 2 and 5. (A) Coomassie blue-stained gel. 
(B) Antibody-stoned nitroceilulose blot. 
level of expression. (Data not shown. This aspect dif- 
fers from our experience with cathepsin B, in which we 
found no expression without induction.) The protein 
was heat-stable and was found in the soluble fraction 
of bacterial lysate after heat treatment (fig.2A), an 
observation similar to recombinant oryzacystatin, a 
cysteine proteinase inhibitor from rice [ 151. Recombi- 
nant human stefin A was characterized by Western 
blotting using a rabbit antiserum to rat low molecular 
weight cysteine proteinase inhibitor and was found to 
be immunoreactive (fig.2B). (This antiserum was 
positive by slot blotting for both purified human stefins 
A and B. Data not shown.) 
Recombinant human stefin A was assayed for its ac- 
tion on cysteine proteinases. It was found to bind to a 
papain-Sepharose column, therefore we used this as a 
single-step rocedure for inhibitor isolation. For a sam- 
ple run on a 2 ml column: a starting material contain- 
ing 29 mg of bacteria1 protein yielded a 0.26 mg 
recombinant protein eluate. (This may be a low 
56 
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estimate due to the saturation of column capacity.) 
Both bacterial ysate (from pMC33) and eluted stefin A 
were found to inhibit human cathepsin B activity, using 
Z-Arg-Arg-AFC as substrate for proteolysis, whereas 
bacterial lysate from control samples (such as pMC34) 
were ineffective (data not shown). Furthermore, inhibi- 
tion constants of the recombinant stefin A were in the 
nanomolar range for papain and cathepsin B (using Z- 
Phe-Arg-AMC, 7-amino-4-methylcoumarin, and Z- 
Arg-Arg-AMC as substrate, respectively, table l), 
similar to those of purified stefin A [16]. Thus, recom- 
binant human stefin A fusion protein was functionally 
active. 
4. DISCUSSION 
Previous attempts to express stefins in bacteria in- 
volved synthetic genes (by chemical synthesis based on 
known amino acid sequences). Recombinant human 
stefin A [17,17a], human stefin B [18,18a] and rat 
stefin A [19] have all been reported. In contrast, our 
result is the first that was derived from human stefin A 
cDNA. One would expect that expression from syn- 
thetic genes should give a larger yield because of the op- 
timization of codon usage for bacteria. However, our 
yield was much higher than that of the human stefin A 
synthetic gene (100 pug from 6 g bacteria), and, in the 
latter, there was no additional synthesis after induction 
[17]. This difference may be due to the choice of ex- 
pression vectors. 
Recombinant stefin A may be used to investigate its 
cellular and physiological functions. For example, a 
chicken cystatin has been shown to stimulate mouse 
fibroblast growth [20]. Recombinant stefin A may have 
potential therapeutic and commercial values, as in the 
skin disease psoriasis, in which a defective stefin A has 
been detected [21], and in cases such as carcinogenesis 
and metastasis [2,22]. In this regard, we have recently 
isolated normal stefin B and defective stefin A from 
human sarcomas [ 161. 
High concentrations of stefin A selectively localized 
Table 1 
Inhibition constants (Ki,,,) for the interaction of recombinant human 
stefin A with papain and human liver cathepsin B 
Enzyme Ki,,, (nM) 
A B 
Papain 0.20 0.23 
Cathepsin B 13.3 10.3 
The inhibition constants were calculated from the Henderson plot of 
V,,/Vi against [I]/1 - Vi/ VO, where VO = activity in the absence of the 
inhibitor, Vi = same but in the presence of the inhibitor at several 
dilutions, [I] = the concentration of the inhibitor. The slope of the 
line through the points = Ki; column A in the table. Alternatively, the 
inhibition constants were calculated according to the procedure of 
Nicklin and Barrett [13]; column B in the table 
in epithelial cells and polymorphonuclear leucocytes 
suggest a defensive role for this inhibitor. Anti-viral 
and anti-bacterial capabilities of cystatins have been 
described [23,24]. There is an abundance of stefin A 
mRNA in chemically induced mouse skin papillomas 
but a decrease in mRNA with progression to car- 
cinomas [8]. We have seen an increase in stefin A 
mRNA expression in UV light-irradiated human 
keratinocytes [7]. Thus, it may be therapeutically 
beneficial to include stefin A as a component of skin 
creams in cosmetics (for use by individuals with pro- 
longed exposure to the sun). Natural proteins, such as 
collagen, have been used as ingredients in cosmetics 
WI. 
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